Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status The ASCO Post
Breakthrough ovarian cancer drug offers patients more time and better quality of life BBC
Carcinosarcoma of the Ovary Arising in the Background of a Mucinous Neoplasm Distinct From a Mural Nodule Cureus
New targeted therapies aim to deliver chemotherapy more precisely for ovarian cancer UCLA Health
From bloating to irregular periods, 6 ovarian cancer symptoms you shouldn't ignore The Times of India
NICE Clears New Drug for Platinum-Resistant Ovarian Cancer Medscape
J&J beats lawsuit alleging talc caused cancer in three women Maryland Daily Record
Elizabethtown couple celebrates first year of marriage, cancer remission with UofL Hospital WAVE News
Ovarian Cancer: Closing Gaps and Advancing Care with RWD Pharmaceutical Executive
CRISPR Shreds Undruggable Cancer Cells with Precision Genetic Engineering and Biotechnology News
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England The Guardian
Rice University receives CPRIT funding to advance cancer research News-Medical
Prosigna Scores, Ovarian Suppression, and Chemotherapy Omission: Iain MacPherson, PhD AJMC
British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy Reuters
Treatment Options for Platinum-Resistant Ovarian Cancer Everyday Health
Ovarian Cancer Jury Told Johnson & Johnson Hid Asbestos Test Results from FDA Mesothelioma.net
J&J beats lawsuit alleging that talc caused three women's cancer Yahoo Finance
Oxford University and Moderna launch trials of vaccine that could prevent cancer The Independent
'Every minute counts when it comes to new ovarian cancer treatment' BBC
ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’ Fierce Biotech
NHS rolls out first new ovarian cancer drug in 20 years EMJ
Evaluation of Physical Activity and Lifestyle Interventions During and After Chemotherapy for Ovarian Cancer: A Systematic Review of Patient Experiences and Clinical Outcomes Cureus
New ovarian cancer treatment dubbed ‘biological missile’ approved fox21online.com
Rethinking ovarian cancer III: the past decade and future directions Nature
Ovarian cancer cells use stress hormone signaling to shut down immune system: Newsroom UT Southwestern Medical Center
New Life-Extending Drug for Women with Ovarian Cancer EMJ
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer Nature
Treatment for chemotherapy-resistant ovarian cancer approved for NHS use The Pharmaceutical Journal
Dr. Sandra Orsulic awarded $1.9M in grants to advance ovarian cancer research UCLA Health
New ovarian cancer treatment dubbed ‘biological missile’ approved Northeast Mississippi Daily Journal
Glycolytic reprogramming in ovarian cancer: mechanisms, immune crosstalk, and therapeutic implications Frontiers
New ovarian cancer treatment dubbed ‘biological missile’ approved themercury.com
ULK1 promotes metastatic progression in experimental models of epithelial ovarian cancer | Oncogene Nature
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial The Lancet
Young adult cancer survivor trusts UT MD Anderson to treat rare ovarian tumor UT MD Anderson
Olympic Ice Dancer Piper Gilles Survived Ovarian Cancer. Here’s What to Know About the Disease. CU Anschutz newsroom
A common cholesterol drug may weaken ovarian cancer defenses Duke University School of Medicine
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study The Lancet
Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome Nature
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development TradingView